Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after ...

Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were ...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 19,247 calls trading, 3x expected, and implied vol ...

A multinational biopharmaceutical corporation, Bristol-Myers Squibb Company (NYSE:BMY) is engaged in product discovery, ...

Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24.

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company ...